MedPath

Place of ECMO in the Management of Severe Refractory ARDS Associated With Covid-19

Completed
Conditions
Respiratory Distress Syndrome
Registration Number
NCT04343404
Lead Sponsor
University Hospital, Strasbourg, France
Brief Summary

Describe COVID-19 patients who are receiving ECMO-VV respiratory replacement and what happens to them.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
100
Inclusion Criteria
  • Patient over the age of 18;
  • Diagnostic COVID-19 by RT-PCR;
  • Hospitalisation in resuscitation for the management of complications related to COVID-19
  • Implanted ECMO-VV during hospitalisation;
  • Patient agreeing to participate in the study
Exclusion Criteria
  • Sujet under guardianship or trusteeship
  • Sujet under safeguard of justice

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Retrospective description of COVID-19 patients receiving respiratory ECMO-VV supplementation and what happens to themFiles analysed retrospectily from March 1st, 2020 to April 15, 2020 will be examined
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Service de Chirurgie Thoracique Nouvel Hôpital Civil Hôpitaux Universitaires de Strasbourg

🇫🇷

Strasbourg, France

© Copyright 2025. All Rights Reserved by MedPath